vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $55.8333.

Several equities research analysts recently commented on the stock. BTIG Research boosted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Lifesci Capital raised shares of vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Finally, Wall Street Zen downgraded shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Saturday, August 8th.

vTv Therapeutics Price Performance

vTv Therapeutics stock opened at $31.80 on Friday. The stock has a market capitalization of $125.29 million, a PE ratio of -30.00 and a beta of 0.29. vTv Therapeutics has a 12 month low of $19.50 and a 12 month high of $44.00. The business has a 50 day simple moving average of $32.39 and a 200-day simple moving average of $34.21.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, equities research analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company’s research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.